Quotient Clinical Expands Data Sciences Capability
News Sep 28, 2016
Quotient Clinical has announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh. The expansion comes in response to growing customer demand for the Data Sciences service. The total Data Sciences headcount has increased by more than 34% during the past two years and is now at over 50 employees. Quotient Clinical is currently actively recruiting. Quotient Clinical’s Data Sciences offering supports its proprietary Translational Pharmaceutics platform, which integrates formulation development, real-time adaptive GMP manufacturing and clinical testing.
The Data Sciences experts provide bespoke services for early phase clinical studies including: data management, eCRF programming, statistics and statistical programming, pharmacokinetic modelling and simulation, and medical writing. These capabilities deliver real-time data to customers for review and interpretation, enabling crucial dosing decisions to be made during the course of a study and to aid development of clinical programs post study.
Greg Johnson, VP Data Sciences, Quotient Clinical, commented: “Our unique Translational Pharmaceutics platform is increasingly being recognised in the industry for reducing clinical development timelines, cutting associated costs, and offering enhanced data-based decision making ability throughout the process. As a consequence, demand for our integrated Data Sciences service is also growing, and we are therefore delighted to announce this expansion and the move to a new larger office, ensuring that customers continue to receive the highest standard of service.”
Translational Pharmaceutics brings innovation to early drug development by integrating formulation development, real-time adaptive GMP manufacturing and clinical testing within a single organisation. Drug products are manufactured in real-time immediately prior to clinical testing, creating the opportunity to modify dose and formulation compositions in response to emerging clinical data (safety, pharmacokinetic or pharmacodynamic). The platform can be applied to a wide range of drug products, including oral, inhaled, dermal and IV, and encompasses simple and complex formulation types.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE